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Abstract
Background: Toll-like receptor (TLR) family members are key players in inflammation. TLR10 has been poorly
studied in chronic inflammatory disorders, and its clinical relevance in rheumatoid arthritis (RA) is as yet unknown.
We aimed at identifying TLR10 variants within all coding regions of the gene in patients with RA as well as
studying their functional and clinical significance.
Methods: TLR10 gene variants were studied by performing sequencing of 66 patients with RA and 30 control
subjects. A selected variant, I473T, was then analyzed in 1654 patients and 1702 healthy control subjects. The
capacity of this TLR10 variant to modify the transcriptional activity of nuclear factor kappa-light-chain-enhancer of
activated B cells (NFkB) was determined by using a luciferase reporter assay and analyzing the expression of NFkB
target genes by quantitative polymerase chain reaction. Differences between groups were analyzed by using the
Mann-Whitney U test and the unpaired two-tailed Student’s t test.
Results: We detected ten missense variants in the TLR10 gene and focused on the I473T substitution based on allele
frequencies and the predicted functional impact. I473T variant is not associated with susceptibility to RA, but it
significantly correlates with erosive disease in patients seropositive for antibodies to citrullinated protein antigens
(p = 0.017 in the total cohort and p = 0.0049 in female patients) and with a lower response to infliximab treatment as
measured by the change in Disease Activity Score in 28 joints (p = 0.012) and by the European League Against
Rheumatism criteria (p = 0.049). Functional studies showed that TLR10 reduced activation of the NFkB inflammatory
pathway in hematopoietic cells, whereas the I473T variant lacked this inhibitory capacity. Consistently, after exposure to
infliximab, cells expressing the I437T variant showed higher NFkB activity than cells carrying wild-type TLR10.
Conclusions: A TLR10 allelic variant, I473T, has impaired NFkB inhibitory activity and is highly associated with disease
severity and low response to infliximab in patients with RA.
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Background
Rheumatoid arthritis (RA) is a systemic autoimmune
disease characterized mainly by chronic inflammation of
the synovial lining and Th1 activation, which lead to
progressive joint destruction. It has been suggested that
viruses and bacteria may contribute to initiation or ex-
acerbation of RA by binding to Toll-like receptors
(TLRs) [1, 2].
TLRs belong to a family of transmembrane proteins that
constitute one of the primary defense mechanisms in in-
fectious and some noninfectious diseases in mammals [3].
Inappropriate activation of TLR-mediated pathways has
been implicated in the loss of self-tolerance, leading to
autoimmunity and chronic inflammation [4, 5]. TLRs are
type I transmembrane glycoproteins with extracellular
leucine-rich repeats (LRRs) and an intracellular Toll/
interleukin (IL)-1 receptor (TIR) homology domain [6].
Signaling by TLRs involves interaction with TIR domain-
containing adaptors, including MyD88, TIR-domain-
containing adapter-inducing interferon-β (TRIF), TRIF-
related adapter molecule (TRAM), TIR-related adapter
protein (TIRAP), and sterile alpha and TIR motif-
containing protein 1 (SARM1) [7]. These interactions
promote nuclear factor kappa-light-chain-enhancer of
activated B cells (NFkB) activation, among other func-
tions. TLR-dependent activation of NFkB drives the pro-
duction of proinflammatory chemokines, cytokines, and
cell adhesion molecules [7, 8]. There is increasing evi-
dence that NFkB is a major, if not the main, transcription
factor controlling inflammation [9].
TLR10 remains the only orphan member among the
human TLRs because its ligands remain unknown and
there are discordant data about its function [10, 11]. The
expression of TLR10 has been reported mainly in B
cells, dendritic cells, eosinophils, neutrophils, and non-
immune cells such as trophoblasts [11–14]. In mam-
mals, TLR10, TLR1, and TLR6 share a common locus
on chromosome 4p14 and are structurally similar to one
another [11]. Despite interacting with MyD88 [11],
TLR10 differs from other TLRs by the lack of a classic
downstream signaling pathway [15]. Phylogeny supports
the idea that TLR10 arose before the gene duplication
that generated TLR1 and TLR6 [16, 17]. TLR1 and
TLR6 are able to form a protein complex with TLR2 and
TLR10 [11, 14], although the individual contribution of
each protein to the function of the complex is largely
unknown.
Genetic variants in TLR family members have been as-
sociated mainly with disease susceptibility in patients
with RA with variable levels of significance and even dis-
cordant results [18–21]. In a previous study, researchers
investigated the association between TLR10 variants and
RA susceptibility, but no statistical significance was
found [20]. Although single-nucleotide variants of the
TLR10 gene have been associated with other auto-
immune [22] and tumor [23] diseases, the functional ac-
tivity of this protein and the clinical significance of its
gene variants are still controversial [11, 24].
In this article, we report that TLR10 is able to inhibit
NFkB signaling in hematopoietic cells, which may limit
the activation of this transcription factor that is involved
in many chronic inflammatory disorders, including RA.
We analyzed the association of a missense variant of
TLR10, I473T, with RA and show that this amino acid
substitution in an LRR domain gives rise to a protein lack-
ing the NFkB inhibition activity that is associated with
more severe disease and lower response to infliximab.
Methods
Samples
In this work, we included two cohorts of patients with
RA, a first cohort of 453 unselected patients followed at
Hospital Universitario Marques de Valdecilla (Santander,
Spain) and Hospital Universitario La Paz (Madrid,
Spain), and a second one of 1201 patients recruited by
the Immune-Mediated Inflammatory Disease Consortium
(Spain) [25]. Clinical information, including demographic
data, disease characteristics, and treatments, are summa-
rized in Table 1. All patients were diagnosed according to
the American College of Rheumatology classification cri-
teria [26]. As a control population, 1702 healthy individ-
uals from the same genetic background were also
genotyped [27]. All control individuals had been screened
for the presence of an autoimmune disease or a family his-
tory of autoimmune disorders, and excluded in case of a
positive result.
Cell lines
K562 and U937 cells were maintained in RPMI 1640
medium (Life Technologies, Paisley, UK) supplemented
with 10 % FBS (Lonza, Verviers, Belgium). The medium
was replaced every 2–3 days.
Sequencing analysis
By next-generation sequencing (NGS), the coding exons
and flanking regions of the TLR10 gene were sequenced
in 66 selected patients with severe RA, rheumatoid fac-
tor and/or antibodies to citrullinated protein antigens
(ACPA) positivity, erosive disease, and resistance to at
least one disease-modifying antirheumatic drug, as well
as in 30 healthy control subjects. DNA libraries were
processed for hybrid enrichment using a custom
Nimblegen SeqCap EZ design (Roche Sequencing, Basel,
Switzerland) containing the coding sequences of TLR10.
Then, double-barcoded libraries were sequenced by
using a MiSeq NGS platform (Illumina, San Diego, CA,
USA). Sequencing reads were aligned against the human
reference genome (hg19) using BWA [28] with the
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default parameters. Several tools (SAM, GATK, Picard)
for manipulating alignments, including sorting, merging,
and indexing the BAM files, were used. Single-
nucleotide variant and indel calling was performed using
GATK Unified Genotyper [29]. Variants were annotated
using snpEff, and association studies were performed
using Plink software [30].
For Sanger sequencing, DNA was extracted from
whole blood by using the QIAamp DNA blood kit
(QIAGEN, Hilden, Germany) and amplified with primers
for human TLR10: 5′-CATGGCCAGAAACTGTGGTC-
3′ and 5′-ACCATCCAACCATCATGACC-3′. Sequence
analysis of amplified fragments was carried by using
a genetic analyzer (Applied Biosystems, Foster City,
CA, USA).
The possible potential impact of an amino acid change
on the encoded protein functions was assessed by using
two different genomic programs: Sorting Intolerant from
Tolerant (SIFT), which uses evolutionary information
from homologous proteins [31], and SNPs3D, based on
both the structure and a sequence-based method that
employs a multiple sequence alignment to build a se-
quence profile [32].
Single-nucleotide polymorphism analysis
TLR10 variant I473T (rs11466657) was analyzed in an
independent cohort of 1201 patients with RA and 1493
healthy control subjects using the TaqMan® genotyping
platform (assay identifier C_25643390_30; Applied Bio-
systems). All polymerase chain reactions (PCRs) and
Table 1 Main features of two cohorts of patients with rheumatoid arthritis
Cohort I (n = 453) Cohort II (n = 1201)
Females, % 73.1 76.8
Mean age, years 65.6 ± 14.5a 46.5 ± 14.5a
Duration of follow-up, months 123.8 ± 91.5a 171.6 ± 123.6a
Extraarticular manifestations, % 22.2 –
Presence of joint damage, % – 100
RF-positive, % 64.8 74.6
ACPA-positive, % 62.2 74.1
Number of previous DMARDs 2.2 ± 1.5a 1.7 ± 1.5a
Number of previous biologic therapies 1.8 ± 1.2a 0.6 ± 0.9a
Abbreviations: RF Rheumatoid factor, DMARDs Disease-modifying antirheumatic drugs, ACPA Antibodies to citrullinated protein antigens
aMean ± SD
Table 2 Sixteen allele variants of the TLR10 gene found by next-generation sequencing in control and rheumatoid arthritis
populations
Reference SNP ID Reference allele Alternative allele MAF p Value AA change Functional class SIFT prediction SNPs3D prediction
rs10776482 A G 0.29 0.2306 D809 Silent nr nr
rs4129008 C T 0.01 0.5652 R799Q Missense − −
rs4129009 T C 0.271 0.1889 I775V Missense − −
rs10776483 A G 0.302 0.3296 H724 Silent nr nr
rs11466658 G A 0.026 0.1599 R525W Missense − −
rs11466657 A G 0.089 0.04327 I473T Missense + +
rs11096955 T G 0.422 0.07296 I369L Missense − −
rs11096956 C A 0.292 0.3918 P344 Silent nr nr
rs11466653 A G 0.026 0.5824 M326T Missense − nr
rs11466652 T C 0.13 0.1403 K303 Silent nr nr
rs11466651 C T 0.026 0.5824 V298I Missense − −
rs11096957 T G 0.438 0.015 N241H Missense − −
rs11466650 A G 0.0005 0.137 L167P Missense + +
rs11466649 C A 0.026 0.5824 A163S Missense − −
rs10856837 C T 0.026 0.5824 T37 Silent nr nr
rs10856838 A T 0.146 0.5813 I13 Silent nr nr
Abbreviations: MAF Minor allele frequency, + Damaging change, − No damaging change, nr No records, SNP Single-nucleotide polymorphism
Torices et al. Arthritis Research & Therapy  (2016) 18:221 Page 3 of 9
endpoint fluorescence readings were performed using
an ABI PRISM 7900 HT sequence detection system
(Applied Biosystems). The genotyping error was esti-
mated by genotyping 20 % of samples in duplicate
(error <1 %) [33].
Transfections and gene reporter assays
TLR10 complementary DNA (cDNA) was cloned into a
pCMV6 vector (OriGene, Rockville, MD, USA). The
I473T variant was generated by site-directed mutagenesis
using the QuikChange mutagenesis kit (Agilent Technolo-
gies, Santa Clara, CA, USA) with the following primers:
5′-GGCCTTACGAGAACTAAATACTGCATTTAATTT
TCTAACTGATC-3′ and 5′-GATCAGTTAGAAAAT
TAAATGCAGTATTTAGTTCTCGTAAGGCC-3′. The
modified insert was sequenced to verify the mutation.
K562 and U937 cells were cotransfected with 2 μg of
wild-type or mutant TLR10 constructs, 1 μg of reporter
plasmid pBVIx-Luc, containing six tandem repeats of
the NFkB recognition sites within the promoter region
linked to the luciferase gene [34] and 0.2 μg of respira-
tory syncytial virus-β-galactosidase plasmid (pRSV-β-gal)
by using Lipofectamine 2000 reagent (Sigma-Aldrich, St.
Louis, MO, USA). After 24 h of transfection, cell viabil-
ity was greater than 80 %. Then, K562 and U937 cells
were incubated with 10 ng/ml and 20 ng/ml tumor ne-
crosis factor-α (TNFα) in the presence or absence of
200 μg/ml infliximab, and, after 24 h, cell extracts
were prepared and analyzed to measure relative lucif-
erase activity by using a dual-light reporter gene assay
system (Applied Biosystems). Results were normalized
for transfection efficiency with values obtained with
pRSV-β-gal.
Expression analyses of NFkB target genes
To assess the expression of individual genes, cDNA was
generated and amplified by using primers for human
TNFα (5′-CAATGGCGTGGAGCTGAGAG-3′ and 5′-
GGCTGATGGTGTGGGTGAGG-3′), chemokine (C-C
motif ) ligand 2 (CCL2) (5′-CTCGCTCAGCCAGATG
CAAT-3′ and 5′-GTCTTCGGAGTTTGGGTTTGC-3′),
TNF-related apoptosis-inducing ligand (TRAIL) (5′-
GAGCTGAAGCAGATGCAGGAC-3′ and 5′-TGACG
GAGTTGCCACTTGACT-3′), and β-actin (5′-GCTG
CCTCAACACCTCAAC-3′ and 5′-GATGGAGTTGAA
GGTAGTTTCGTG-3′). Quantitative real-time PCR was
performed using the ABI PRISM 7000 Sequence Detec-
tion System (Applied Biosystems). The ratio of the abun-
dance of differentiation markers to that of β-actin
transcripts was calculated as 2n, where n is the threshold
cycle value of β-actin minus the threshold cycle value of
the corresponding messenger RNA (mRNA) and nor-
malized by the value of the sample with the lowest ex-
pression level of these genes. The specificity of the
desired PCR products was determined by performing
melting curve analysis.
Statistical analysis
All statistical analyses were performed using the SPSS 20
software program (IBM, Armonk, NY, USA) and the R
statistical software package (version 3.2.0). Differences in
categorical variables between groups of patients were
compared using Fisher’s exact test. Statistical signifi-
cance between groups in in vitro analyses was deter-
mined by using an unpaired, two-tailed Student’s t test
or the Mann-Whitney U test. The significance level was
set at p < 0.05. Genetic association analyses were per-
formed using linear and logistic regression models. The
significance of the β regression coefficient was deter-
mined using the Wald test. As described previously, co-
variates in these genetic analyses included the years of
disease evolution and the basal Disease Activity Score in
28 joints (DAS28) for the association of rs11466657
genotype with the level of joint damage [33] and the
change in DAS28 at 12 weeks [35], respectively.
Fig. 1 TLR10 gene variants. a Schematic representation of TLR10
protein that illustrates the position of the missense variants identified by
next-generation sequencing. b Genotype distribution of the I473T variant
in the independent cohort of 1493 healthy control subjects (HC) and
1201 patients with rheumatoid arthritis (RA). c TLR10 genotype
frequencies in HapMap populations. The following population samples
were included: CEU (Utah residents with Northern and Western
European ancestry from the Centre d’etude du Polymorphisme Humain
[CEPH] collection), HCB (Han Chinese in Beijing), JPT (Japanese in Tokyo,
Japan), YRI (Yoruba in Ibadan, Nigeria), TSI (Toscani in Italy). LRR Leucine-
rich repeats, TLR Toll-like receptor, TM Transmembrane domain, TIR Toll/
interleukin-1 receptor domain
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Results
I473T variant is associated with disease severity and
treatment response in patients with RA
The function of TLR10 is controversial, and its associ-
ation with RA has been poorly studied. In order to as-
sess whether TLR10 variants contribute to modifying
the course of the disease in patients with RA, we se-
quenced the coding exons of the TLR10 gene in 66 se-
lected patients with RA and 30 healthy control subjects.
After filtering bases having at least 30× sequence cover-
age, 16 variants were identified (Table 2). The power to
detect genetic effects depends to a great extent on the
minor allele frequency (MAF) of the risk allele tested.
Ten of the sixteen variants filtered corresponded to mis-
sense changes, which are located mainly in LRR domains
(Fig. 1a); of these, only two, I473T and L167P, were pre-
dicted by using the SIFT and SNPs3D programs to have
a functional impact on the protein. The MAF of the
L167P variant was less than 0.1 %, whereas the MAF of
I473T was about 9 %. Thus, we decided to focus on the
I473T variant for clinical association studies.
First, we studied a population of 453 patients and
found that the genotype frequencies (86.6 % AA, 11.9 %
AG, 1.5 % GG) were not significantly different from
those in a population of 209 control subjects (84.5 %
AA, 14.3 % AG, 1.2 % GG). This result was confirmed
by analyzing the largest genome-wide association study
(GWAS) meta-analysis performed to date, which in-
cluded 29,880 RA cases and 73,758 control subjects [36].
Using the available summaries for the GWAS data in the
Caucasian European population, we found no associ-
ation between the I473T variant and RA susceptibility
(p = 0.26). We then analyzed a number of clinical
findings in the patient population associated with disease
severity, including the presence of typical RA autoanti-
bodies, extraarticular manifestations, and the need for
specific biologic treatments and surgery. Although differ-
ences between AA + AG and GG genotypes did not
reach statistical significance (p ≥ 0.2), all five clinical cri-
teria showed the same tendency associated with more
severe disease only in GG genotype carriers (Fig. 2a). To
strengthen this observation, we studied a larger cohort
of 1201 patients with RA and 1493 healthy control sub-
jects. As previously observed, the genotype distribution
was found to be similar in both patient and control pop-
ulations (Fig. 1b), which is consistent with the genotypes
described for the European population in the HapMap
database (Fig. 1c). Interestingly, as shown in Fig. 2b, the
I473T variant is highly associated with erosive disease in
ACPA-positive patients with RA (p = 0.017 in the total
Fig. 2 Association of the I473T variant with disease severity in patients with RA. a Frequency of clinical parameters associated with severity in
AA + AG and GG genotypes in a cohort of 453 patients. Differences were analyzed with the Fisher’s exact test. RF+ Positive for (high levels of)
rheumatoid factor, ACPA+ Seropositive for antibodies to citrullinated protein antigens. b Disease severity associated to the G allele in 1201
patients with RA. The β value (regression coefficient), used to evaluate the effect of I473T variant (genetic risk), was estimated for a number of
clinical findings. A positive regression coefficient means that the variant increases risk. Dotted lines indicate cutoff values. Clinical parameters were
categorized as binary variables. Significance of the β value was determined by using the Wald test. Eccp/years Association with erosions in ACPA+
patients including the years of disease evolution; Eccp/years-women Association with erosions in ACPA+ female patients including the years of
disease evolution, IFX-EULAR Association with response to infliximab (European League Against Rheumatism response criteria: moderate/good vs
none), IFX-DAS28 Association with change in Disease Activity Score in 28 joints in patients treated with infliximab
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cohort and p = 0.0049 in female patients) and with a
lower response to infliximab treatment as measured by
the change in DAS28 score (p = 0.012 in the total co-
hort) as well as by the European League Against
Rheumatism response criteria (p = 0.025 in the total co-
hort), which indicate that this variant is represented in a
group of patients with more severe disease.
Variant I437T modifies the NFkB regulatory capacity of
TLR10
On the basis of a three-dimensional structure model vi-
sualized by using the Jmol viewer (Fig. 3a), we found
that position 437 is within a β-strand in the LRR18 do-
main and is occupied by an isoleucine, a highly hydro-
phobic amino acid, buried inside the protein core. This
position is occupied by hydrophobic amino acids in
TLR10 (Ile), TLR2 (Ile), and TLR1 (Val), which belong
to the same subfamily of TLRs that are located at the
cell membrane and dimerize with each other [37]. In the
TLR10 variant, isoleucine is substituted by threonine, a
polar amino acid that may participate in hydrogen bonds
and is usually located at the protein surface. LRR do-
mains provide an outstanding framework for achieving
diverse protein interactions. Thus, this structural change
decreases hydrophobic contacts and may alter function-
ally relevant protein-protein interactions. TLR family
members are known to be regulators of the NFkB activ-
ity, a key pathway in inflammation. To experimentally
prove the functional consequences of the I437T variant
on the activation of NFkB, we introduced the codon-
altering nucleotide in a construct containing TLR10
cDNA by site-directed mutagenesis and studied the cap-
acity of this variant to modify the NFkB transcriptional
activity. As shown in Fig. 3b and c, wild-type TLR10
downregulates the transcriptional activity of NFkB after
stimulation with an inflammatory cytokine, TNFα, in
K562 and U937 hematopoietic cell lines, which are
widely used to study NFkB activation [38]. However, the
I437T substitution blocks the inhibition capacity of
TLR10. In order to translate the reduced response to
infliximab in patients to our in vitro model, we stimu-
lated cells with TNFα in the presence or absence of
infliximab. Consistently, cells expressing the I437T vari-
ant had a higher level of NFkB activity remaining after
treatment with infliximab than cells expressing the wild-
type variant (Fig. 3d, e). Next, we confirmed this result
Fig. 3 Regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) transcriptional activity by the I473T variant. a Three-
dimensional structure of Toll-like receptor 10 (TLR10) visualized by using the Jmol viewer showing the location of residue I473. NAG 2-(acetyla-
mino)-2-deoxy-β-D-glucopyranose. b and c K562 and U937 cells were cotransfected with wild-type (wt) TLR10 or its mutated variant (mut) and a
reporter vector containing NFkB-responsive sequences. Cells were stimulated with 10 ng/ml tumor necrosis factor-α (TNFα) for 24 h, and then cell
extracts were prepared and analyzed for luciferase activity. d and e K562 and U937 cells transfected with the indicated TLR10 variants were
treated with TNFα in the presence or absence of infliximab, and luciferase activity was analyzed. Histograms show the mean + SD of three
independent experiments. *p < 0.05
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by analyzing the expression of NFkB target genes. The
expression levels of CCL2, TRAIL, and TNFα were
downregulated in the presence of wild-type TLR10 fol-
lowing stimulation of the NFkB pathway with TNFα
(Fig. 4a–e). In line with our previous results, downregu-
lation of NFkB target genes was abrogated when U937
and K562 cells where transfected with the variant-
containing construct and cultured with TNFα (Fig. 4a–
e). Moreover, gene expression also confirmed that the
TLR10 variant slightly reduced the response of TNFα-
activated cells to infliximab (Fig. 4f ). Overall, the in vitro
data show that the I437T variant abrogates the NFkB in-
hibition activity of TLR10 and displays a weak but con-
sistent resistance to the anti-inflammatory effects of
infliximab.
Discussion
Deciphering the mechanisms that regulate the activity of
NFkB is of major importance for understanding the re-
sponse to inflammatory stimuli. TLRs have been sug-
gested to be implicated in responses to pathogens in RA
[39]. Nowadays, TLR10 is the only member of the TLR
family without a well-defined biological function. In this
study, we show that TLR10 displays NFkB inhibitory ac-
tivity in hematopoietic cells following treatment with
inflammatory stimuli. Researchers in several studies have
described how TLR10 acts as a proinflammatory recep-
tor activating NFkB signaling [11, 40]. Another study
showed that TLR10 fails to activate typical TLR-induced
signaling, including transcriptional activation mediated
by NFkB or interferon-β [15]. Recently, it has been
shown that TLR10 is a modulator with mainly inhibitory
effects [24]. In line with this, blocking TLR10 by antag-
onistic antibodies enhances proinflammatory cytokine
production [10]. Also, evidence has been provided indi-
cating that TLR10 induces apoptosis through activation
of caspase-3 [18], which is consistent with the NFkB in-
hibitory activity of TLR10 because NFkB is an antiapop-
totic transcription factor. These contradictory results
may be due to the complexity of the modulatory effects
of TLR10 that involve several mechanisms, including
competition for ligands, heterodimerization with other
TLRs, and activation of different signaling pathways.
On the basis of this information, the cell model used
to study TLR10 may be relevant to evaluation of the
functional activities of this receptor and should be taken
into consideration when comparing different studies re-
garding the activities of TLR10. Researchers in several
studies have investigated the role of TLR polymorphisms
in RA, although the results obtained are controversial
Fig. 4 Regulation of the levels of nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) target genes by the I473T variant. U937
and K562 cells were transfected with Toll-like receptor 10 (TLR10) (wild type [wt] or mutated variant [mut]) and then treated or not with 20 ng/ml
tumor necrosis factor-α (TNFα) for 24 h. The expression of NFkB target genes chemokine (C-C motif) ligand 2 (CCL2) (a, d), TNF-related apoptosis-
inducing ligand (TRAIL) (b, e), and TNFα (c) were determined by performing quantitative real-time polymerase chain reactions. f Cells transfected
with the indicated variants were treated with TNFα in the presence or absence of infliximab, and, 24 h later, the messenger RNA (mRNA) levels of
CCL2 were determined. β-actin was used for normalization. C Cells transfected with empty vector as an additional control. Histograms show the
mean ± SD of three independent experiments. *p < 0.05
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[19–21, 41]. However, TLR10 genetic variants have not
yet been associated with RA, but they have been associ-
ated with susceptibility to infectious and inflammatory
diseases such as extrapulmonary tuberculosis and
asthma [42, 43]. We found that the I473T variant signifi-
cantly associates with the presence of ACPA and erosive
disease, both in the total RA cohort and in female pa-
tients. It is well established that TNFα inhibitors help
control disease activity. However, not all patients re-
spond adequately to initial anti-TNFα treatment [44]. In
line with this, we have demonstrated that patients with
the I437T variant showed a significant lower response to
infliximab, and this effect was also demonstrated in
vitro. Thus, this TLR10 variant may be a good candidate
marker of response to infliximab or other anti-TNFα
treatment in patients with RA, which should be vali-
dated by replicating this study in other populations with
different genetic backgrounds. Although there were no
differences in genotype distribution between patients
with RA and healthy control subjects, our data show
that a TLR10 genetic variant selects a group of patients
with a more severe and refractory disease. This variant
has been described only in previous work associated
with a decreased risk of meningioma [45]. The I473T
variant leads to a reduced capacity of TLR10 to inhibit
activation of NFkB in response to inflammatory stimuli.
This effect may be explained by the amino acid change
decreasing the hydrophobicity of an LRR domain, which
may alter the interaction with TLR proteins needed for
TLR10 signaling [37].
Conclusions
Overall, our observations identify an allelic variant,
I473T, in TLR10 that is significantly associated with
more severe disease. Our data also indicate that the
TLR10 variant lacks the capacity to inhibit NFkB tran-
scriptional activity in hematopoietic cells and reduces
the clinical and biological response to infliximab, which
support the association between the I473T variant and
disease outcome in patients with RA.
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